Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 9, 2004 - Issue 2
Submit an article Journal homepage
125
Views
13
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for narcolepsy

Vivien C Abad Camino Medical Group, Clinical Monitoring Sleep Disorders Center, Cupertino, California, USA
&
Christian Guilleminault Stanford University Sleep Research Center and Sleep Disorders Clinic Stanford, Training and Clinical Research, California, USA
Pages 281-291 | Published online: 24 Feb 2005

Bibliography

  • BLACK J, THORPY M: Understanding narcolepsy: a review of recent advances. 17th Annual American Professional Sleep Societies Meeting. Chicago, Illinois, USA (3–8 June 2003).
  • MERRITT SL, BERGER BE, PONNAGANTI V, RASAMIMARI A: Mood, perceived stigma and health status self-disclosure of young adults with narcolepsy. Sleep (2004)27(Abstract Suppl.):5A240.
  • TAHERI S, ZEITGER JM, MIGNOT E: The role of hypocretins (orexins) in sleep regulation and narcolepsy. Ann. Rev Neurosci. (2002) 25:283–313.
  • AMERICAN ACADEMY OF SLEEP MEDICINE: International classification of sleep disorders, revised: diagnostic and coding manual. American Academy of Sleep Medicine, Chicago, Illinois, USA (2001):38–43.
  • GUILLEMINAULT C, MIGNOT E, PARTINEN M: Controversies in the diagnosis of narcolepsy. Sleep (1994) 17\(Suppl. 8):S1–56.
  • BROOKS S, MIGNOT E: Narcolepsy and idiopathic hypersomnia. In: Sleep Medicine. Lee- ChiongT, Sateia M, Carskadon M (Eds), Hanley & Belfus, Inc., Philadelphia, PA, USA (2002):193–202.
  • BROOKS S, BLACK J: Novel therapies for narcolepsy. Expert Opin. Invest. Drugs. (2002) 11(12):1821–1827.
  • •Concise review of novel therapies for narcolepsy.
  • NISHINO S, OKURA M, MIGNOT E: Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med. Rev (2000) 4(1):57–99.
  • ••Useful background for pharmacologicalcompound development innarcolepsy treatment.
  • OVEREEM S, MIGNOT E, VAN DIJK JG, LAMMERS GJ: Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives.' Clin. Neurophysiol (2001) 18(2):78–105.
  • DAUVILLIERS Y, CARLANDER B, MOLINARI N et al.: Month of birth as a risk factor for narcolepsy. Sleep (2003) 26(6):663–665.
  • PACK Al, BLACK JE, SCHWARTZ JR, MATHESON JK: Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am. j Respic Crit. Care Med. (2001) 164(9):1675–1681.
  • RUGINO TA, SAMSOCK TC: Modafinil in children with attention-deficit hyperactivity disorder. Pediatc Neurol (2003) 2:136–142.
  • TURNER DC, CLARK L, DOWSON J, ROBBINS TW, SAHAKIAN BJ: Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol. Psychiatry(2004) 55(10):1031–1040.
  • SCHWEITZER JB, HOLCOMB HH: Drugs under investigation for attention-deficit hyperactivity disorder. Carr: Opin. Investig. Drugs (2002) 3(8):1207–1211.
  • BASSETTI C, ALDRICH MS: Narcolepsy. Neurol Clin. (1996) 14(3):545–571.
  • PARKES D: Introduction to the mechanism of action of different treatments ofnarcolepsy. Sleep (1994) 17(Abstract Supp 1.):593–596.
  • MITLER MM, ALDRICH MS, KOOB GE ZARCONNE VP: Narcolepsy and its treatment with stimulants. ASDA Standards of Practice. Sleep (1994) 17(4):352–371.
  • ••Practice parameters for stimulant usein narcolepsy.
  • SCAMMELL T: The neurobiology,diagnosis, and treatment of narcolepsy. Ann. Neurol (2003) 53(2):154–166.
  • •Comprehensive review of narcolepsy.
  • SCAMMELL TE, ESTABROOKE IV, MCCARTHY MT et al.: Hypothalamic arousal regions are activated during modafinil-induced wakefulness. Neurosci (2000) 20(22):8620–8628.
  • WISOR J, NISHINO S, SORA I, UHL G, MIGNOT E, EDGAR D: Dopaminergic role in stimulant-induced wakefulness. Neurosci. (2001) 21(5):1787–1794.
  • MIGNOT E, NISHINO S,GUILLEMINAULT C, DEMENT WC: Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep (1994) 15(5):436–437.
  • STONE EA, COTECCHIA S, LIN Y, QUARTERMAIN D: Role of brain alpha 1 B-adrenoceptors in modafinil-induced behavioral activity. Synapse (2002) 46(4):269–270.
  • GALLOPIN T, LUPPI PH, RAMBERT FA, FRYDMAN A, FORT P: Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep (2004) 27(1):19–25.
  • IVANENKO A, TAUMAN R, GOZAL D: Modafinil in the treatment of excessivedaytime sleepiness in children. Sleep Med.(2003) 4(6):579–582.
  • WICHNIAK A, BRUNNER H, FRIESS E, POLLMACHER T: Successful suppression of cataplectic attacks with tramadol. Neurology(2003) 61(6):864–865.
  • MONTPLAISIR J, GODBOUT R: Nocturnal sleep of narcoleptic patients: revisited. Sleep (1986) 9(1 Pt 2):159–161.
  • MANFREDI RL, KALES A: Clinical neuropharmacology of sleep disorders. Semin. Neurol (1987) 7(3):286–295.
  • BROUGHTON WA, BROUGHTON RJ: Psychosocial impact of narcolepsy. Sleep (1994) 17(Abstract Suppl.):S45–S49.
  • ALDRICH MS: Narcolepsy. N Engl. .1 Merl (1990) 323(6):389–394.
  • NO AUTHORS LISTED: A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep (2002) 25(1):42–49.
  • SCHARF MB: Assessment of sodium oxybate for the long-term treatment of narcolepsy. Sleep (2001)23(Abstract Suppl.):A234.
  • US XYREM MULTICENTER STUDY GROUP: A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep (2003) 26(1):31–35.
  • US XYREM MULTICENTER STUDY GROUP: Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. (2004) 5(2):119–123.
  • HORNFELTDT C, PERTILE T: Lack of withdrawal symptoms following abrupt cessation of therapeutically administered sodium oxybate. Sleep (2001)24(Abstract Suppl.):A236.
  • BLACK J, RISTANOVIC R,MAMELAK M, MONTPLAISIR J: Dose response effects of sodium oxybate on polysomnographic (PSG) measures in narcolepsy patients; preliminary findings. Sleep (2001) 24(Abstract Suppl.):A321.
  • HAYDUK R, MITLER MM: Sodium oxybate therapy improves the quality of life of narcolepsy patients. Sleep (2001) 24(Abstract Suppl.):A326.
  • RISTANOVIC RA, BLACK J,MAMELAK M, MONTPLAISIR J: Effect of increasing doses of sodium oxybate on nocturnal respiratory disturbances. Sleep (2002) 25(Abstract Suppl.):A473–A474.
  • BLACK J, RISTANOVIC, MAMELAK M,MONTPLAISIR J: Effect of increasing doses of sodium oxybate on nocturnal oxygen saturation: preliminary findings. Sleep (2002) 25(Abstract Suppl.): A474–A475.
  • MITLER MM, HAJDUKOVIC R: Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep (1991) 14(3):218–220.
  • AUGER R, GOODMAN SH, SILBER MH, KRAHN LE,SLOCUMB NL: Risks of high dose stimulant use for disorders of excessive somnolence: a case-control study. Sleep (2004) 27(Abstract Suppl.):A241.
  • US FOOD AND DRUGADMNISTRATION: Pregnancy categories for prescription drugs. FDA Drug Bull. (1982) 12:24–25.
  • BRIGGS GG, FREEMAN RK, YAFFE SJ: Drugs M Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Rick. Briggs GG, Freeman RK, Yaffe SJ (Eds), Williams and Wilkins, Baltimore, MD, USA (1990).
  • EICHLESEDER W: Ten years experience with 1000 hyperactive children in a private practice. Pediatrics (1985) 76:176–184.
  • GUILLEMINAULT C, PELAYO R: Narcolepsy in children: a practical guide to its diagnosis, treatment, and follow-up. Paediatr. Drugs (2000) 2(1):1–9.
  • BROUGHTON R, VALLEY V, AGUIRRE M, ROBERTS J,SUWALSKI W, DUNHAM W: Excessive daytime sleepiness and the pathophysiology of narcolepsy/cataplexy: a laboratory perspective. Sleep (1986) 9(1):205–215.
  • HISHIKAWA Y, SHIMUZU T: Physiology of REM sleep, cataplexy, and sleep paralysis. Adv. Nemo]. (1995) 67:245–271.
  • LECENDREUX M, MARET S,BASSETTI C, MOUREN MC, TAFTI M: Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. Sleep Res. (2003) 12(4):347–348.
  • •Landmark case for WIG use in narcolepsy.
  • PEYRON C, TIGHE DK,VAN DEN POL AN et al.: Neurons containing hypocretin (orexin) project to multiple neuronal systems. Neurosci. (1998) 18(23):9996–10015.
  • RIPLEY B, OVEREEM S, FUJIKI N et al: CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology (2001) 57(12):2253–2258.
  • MIGNOT E, LAMMERS GJ, RIPLEY B et al.: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol (2002) 59(10):1553–1562.
  • PEYRON C, FARACO J, ROGERS W et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. (2000) 6(9):991–997.
  • THANNICKAL TC, MOORE RY, NIENHUIS R et al.: Reduced number of hypocretin neurons in human narcolepsy. Neuron (2000) 27(3):469–474.
  • THANNICKAL TC, SIEGEL JM, NIENHUIS R, MOORE RY: Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol (2003) 13(3):340–351.
  • GRUNER JA, CHATTERJEE S, AAM ONE LD et al.: Novel wake promoting and cortical activating agents lacking dopaminergic activity. 17th Annual American Professional Sleep Societies Meeting. Chicago, Illinois, USA (3–8 June 2002).
  • SHIBA T, FUJIKI N, WISOR JP, DALE EM, SAKURAI T, NISHINO S: Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep (2004)27(Abstract Suppl.):SA241-SA242.
  • MURILLO-RODRIZUEZA E, ARIAS-CARRION O, XU M, BLANCO-CENTURION C, DRUCKER-COLIN R, SHIROMANI PJ: Time course of survival of hypocretin neuronal transplants into the pons of adult rats. Sleep (2004) 27(Abstract Suppl.):A239.
  • ADAM K, OSWALD I: Protein synthesis, bodily renewal and the sleep-wake cycle. Clin. Sci. (1983) 65(6):561–567.
  • LAMMERS GJ, ARENDS J,DECLERCK AC, KAMPHUISEN HA, SCHOUWINK G, TROOSTJ: Ritanserin, a 5-HT2 receptor blocker, as add-on treatment in narcolepsy. Sleep (1991) 14(2):130–132.
  • VAN LAAR M, VOLKERTS E, VERBATEN M: Subchronic effects of the GABA agonist lorazepam and the 5-HT2A/c antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers.Psychopharmacology (2001)154(2):189–197.
  • LAND OLT HP, METER V, BURGESS HJ et al.: Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology (1999) 21(3):455–466.
  • MONTI JM, MONTI D: Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med. Rev (2004) 8(2):133–148.
  • FOLDVARY-SCHAEFER N,DE LEON SANCHEZ I, KARAFA M, MASCHA E, DINNER D, MORRIS HH: Gabapentin increases slow-wave sleep in normal adults. Epilepsia (2002) 43(12):1493–1497.
  • WALSH JK, ZAMMIT G, ROTH T: Sleep-consolidating effects of tiagabine in patients with primary insomnia. Sleep (2004) 27(Abstract Suppl.):5A256-5A257.
  • SCHULZ H, STOLZ C, MULLER J: The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry (1994) 27(4):147–151.
  • CHANG FC, OPP MR: IL-1 is a mediator of increases in slow-wave sleep induced by CRH receptor blockade. km Physic] Regul Integr. Comp. Physiol (2000) 279(3):R793–R802.
  • HECHT M, LING L, KUSHIDA C et al:Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep (2003) 26(7):809–810.
  • MIGNOT E: Pathophysiology of narcolepsy. In: Principles and Practice of Sleep Medicine. Ord ed). Kryger M, Roth T, Dement WC (Eds), WB Saunders Company, Philadelphia, PA, USA (2000):663–675.

Websites

  • http://www.neurologicalalliance.org.uld docs/neuronumbers/neuro_numbers.doc Neurologic Alliance.Page 7: Publication date: April 2003.
  • http://www.census.govUS Census Bureau Population Division.
  • http://www.statistics.gov.uk National Statistics online.
  • http://www.orphanmedical.org Orphan Medical, Inc. Annual Statement 2002.
  • http://www.cephalon.org Cephalon. Annual Statement 2003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.